The firm also said its partner BioNTech won't exercise its option rights for the CD19- and CD22-directed CAR T-cell therapy candidate AUTO1/22.

An intravenous form of the gene therapy is already approved and sold as Zolgensma in the US for patients less than 2 years of age.

The firm's LLM-based platform abstracted complex information from medical charts with up to 100 percent accuracy in a pilot study of breast cancer patients.

The firm is also shuttering its allogeneic cell therapy platform and has tasked a new CEO to lead the company through a merger.